Effect of nebolized G-CSF in treatment of Ventilator Associated Pneumonia (VAP)

Comparison the effects of Meropenem, intravenous Colistin plus nebolized Colistin and Meropenem, intravenous Colistin plus nebolized Granulocyte Colony Stimulating Factor(G-CSF ) on treating patients with Ventilator Associated Pneumonia (VAP) due to multidrug_resistance Acinetobacter

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150824023743N2

Enrollment

Registered

2019-07-31

Start date

2017-04-21

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator associated pneumonia. other infectious diseases

Interventions

Intervention 1: Intervention group: In this group patients that received Meropenem (Dana company) 2g every 8 hour , injectable Colistin ( Exir company) 4.5 million IU every 12 hour, plus nebuliz

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Mechanical ventilation more than 48 hours Multidrug resistance Acinetobacter in tracheal culture Satisfaction with the first class family

Exclusion criteria

Exclusion criteria: Allergy to Colistin Other infections

Design outcomes

Primary

Measure	Time frame
Achieve in treatment. Timepoint: 1,3,5,7 and 14 days after intervention. Method of measurement: Calculate the Clinical Pulmonary Infection Score table.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Mohajeri

Esfahan University of Medical Sciences

mohajerifatemeh4@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 15, 2026